Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multinational European trial for children with opsoclonus myoclonus syndrome / dancing eye syndrome
2011-000990-29Phase 3Completed
- Sponsor
- Institut Curie
- Start
- Sep 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of cyclophosphamide, dexamethasone and rituximab in Opsoclonus myoclonus syndrome (OMS), sponsored by Institut Curie. Primary endpoint: Primary response at 48 weeks. Started Sep 2012; status: completed.
02
Drugs
cyclophosphamidedexamethasonerituximab
03
Conditions
Opsoclonus myoclonus syndrome (OMS)
Beyond the preview
Go deeper on 2011-000990-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000990-29.